Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Neoplasms × guadecitabine × Clear all

Phase

Status

Sponsor Class

OTHER 1 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 3 Ovarian Neoplasms 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 96 Carboplatin 90 pembrolizumab 52 Bevacizumab 50 liposomal doxorubicin 48 olaparib 34 Gemcitabine 31 niraparib 28 Topotecan 25 Nivolumab 20 Cisplatin 19 Doxorubicin 16 Drug Therapy 14 Docetaxel 14 1-dodecylpyridoxal 13 Cyclophosphamide 12 avelumab 11 Fulvestrant 10 oregovomab 9 veliparib 8 atezolizumab 8 Oxaliplatin 8 Cetuximab 8 rucaparib 7 mirvetuximab soravtansine 7 fluzoparib 7 Injections 7 Fluorouracil 7 130-nm albumin-bound paclitaxel 7 trebananib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01696032 2024-08-27

SGI-110

Astex Pharmaceuticals, Inc.

Phase 2 Completed

120 enrolled 22 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡